Comparing etanercept and tofacitinib in adults with rheumatoid arthritis
Tests etanercept and tofacitinib in adults with rheumatoid arthritis over time.
Plain-language title generated from the registry record
Registry title: Advanced Therapeutics in Rheumatoid Arthritis (RA)
Key facts
- Where
- London, CanadaSee the site
- Phase
- Phase 4
Where in Canada
- Rheumatology Clinic, St. Joseph's Health CareLondon, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Trial code
- NCT03976245
- Record updated
- 29 November 2024
- Original description
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).Read full original descriptionShow less
Advanced Therapeutics in Rheumatoid Arthritis (RA)
This study will evaluate the retention rates of two advanced therapies, Tumour Necrosis Factor (TNF) and Janus kinase inhibitor (JAK) in the treatment of adults with Rheumatoid Arthritis (RA) over a two year period. It will also examine the ability to embed a clinical trial in a clinical situation using an electronic medical record (EMR).
Inclusion: patients with RA who meet criteria for obtaining an advanced therapeutic through usual care; active RA with 5 or more swollen joints; seropositive; presence of erosions; failure of methotrexate and hydroxychloroquine and sulfasalazine; failure of Leflunomide; -> or equal to 18 years; able to provide consent; able to attend usual follow up visits.
Exclusion: previous use of an advanced therapeutic (biologic or JAK kinase inhibitor); active serious infection; active Tuberculosis; current cancer; less than 18 years of age; no contraindication to etanercept or tofacitinib; multiple sclerosis; lymphoma ever; unable to provide consent.